3,4-dihydro-1H-naphthalene derivatives as a highly selective...

Details 3,4-dihydro-1H-naphthalene derivatives as a highly selective... 3,4-dihydro-1H-naphthalene derivatives as a highly selective...

2002-10-03

2004-02-03

McKane, Joseph K. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Sulfinate esters

C558S410000

Reexamination Certificate

active

06686493

ABSTRACT:

TECHNICAL FIELD
The present invention relates to 3,4-dihydro-1H-naphthalene derivatives as a highly selective cyclooxygenase-2 inhibitor.
BACKGROUND
Most of non-steroid anti-inflammatory drugs represent actions such as anti-inflammation, ataralgesia, defervescence by inhibiting the enzymatic activity of cyclooxygenase or prostaglandin G/H synthase. In addition, they can suppress the uterine contraction induced by hormones and the cell proliferation in several kinds of cancers. First, only cyclooxygenase-1 was known to be found in cow as a constitutional enzyme. But, recently, cyclooxygenase-2 is elucidated as an induced form. Cyclooxygenase-2 is identified to be discriminated clearly from cyclooxygenase-1 and can be provoked easily by mitogen, endotoxin, hormones, growth factors, cytokines and the like.
Prostaglandins have various pathological and physiological functions. Precisely, cyclooxygenase-1 as a constitutional enzyme participates in the secretion of basic endogenous prostaglandin and plays an important role in physiological aspects such as stomach homeostasis, renal blood circulation and so on. On the other hand, cyclooxygenase-2 is induced by inflammatory factors, hormones, growth factors, cytokines and the like and thus plays an important role in pathological effects of prostaglandins. Therefore, selective inhibitors against cyclooxygenase-2 are expected to have no side effect on account of the functional mechanism compared with the anti-inflammatory drugs such as conventional non-steroid agents and to represent actions such as anti-inflammation, ataralgesia and defervescence. Furthermore, it is estimated to suppress the uterine contraction induced by hormones and the cell proliferation in several kinds of cancers. Especially, it probably has lesser side effects such as gastrointestinal toxicity, renal toxicity and the like. Also, it is assumed to prevent the synthesis of contractive prostanoids and thus inhibit the contraction of smooth muscle induced by the prostanoid. Hence, it can be applied usefully to treat a premature birth, dysmenorrhea, asthma and several diseases associated with eosinophilic leukocytes. Besides, it can be exploited widely to cure osteoporosis, glaucoma and athymia, which has been disclosed in a lot of references, especially the usefulness of selective inhibitors against cyclooxygenase-2 (References: John Vane, “Towards a better aspirin” in
Nature
, Vol. 367, pp 215-216, 1994; Bruno Battistini, Regina Botting and Y. S. Bakhle, “COX-1 and COX-2; Toward the Development of More Selective NSAIDs” in
Drug News and Perspectives
, Vol. 7, pp 501-512, 1994; David B. Reitz and Karen Seibert, “Selective Cyclooxygenase Inhibitors” in
Annual Reports in Medicinal Chemistry
, James A. Bristol, Editor, Vol. 30, pp 179-188, 1995).
The selective inhibitors against cyclooxygenase-2 have been reported to have various structural forms. Among these, the diaryl heterocycle structure, namely a tricyclic system, has been studied most frequently and exploited to construct a lot of candidate substances. In this structure, it is essential that sulfonamide or methanesulfone group exist onto one phenyl group. The initial substance of such a structure is identified to be Dup697 (Bioorganic and Medicinal Chemistry Letters, Vol. 5, No. 18, p 2123, 1995). Then, as a derivative, SC-58635 (Journal of Medicinal Chemistry, Vol. 40, p 1347, 1997) having a pyrrazole structure, MK-966 (WO 95/00501) having a furanone structure and the like are disclosed.
DISCLOSURE OF INVENTION
Based upon the above technical backgrounds, the inventors of the present invention have tried a lot in order to develop novel compounds as a highly selective cyclooxygenase-2 inhibitor. As a result, we have found that 3,4-dihydro-1H-naphthalene derivatives of formula 1 and formula 2 satisfied such a purpose and completed the present invention successfully. It was identified that the compounds of the present invention contain sulfoneamidophenyl or methanesulfonylphenyl group as a specific structure of conventional chemicals and namely, is based upon a structure fused in between two or three rings which is very different from typical tricycle structures.
Therefore, the object of the present invention is to provide 3,4-dihydro-1H-naphthalene derivatives of formula 1 and formula 2 as depicted below.
Hereinafter, the present invention will be described more clearly.
The present invention relates to 3,4-dihydro-1H-naphthalene derivatives of formula 1 and formula 2.
Wherein, R
1
is methyl or amino group,
R
2
is hydrogen, halogen (fluoride, chloride, bromide and so on), C
1
-C
3
-alkyl (methyl, ethyl and so on) substituted or not substituted by halogens, amino, hydroxy, hydoxycarbonyl, nitro or cyano group,
X is oxygen (═O), sulfur (═S) or oxime (═N—OH) as a substituted or not substituted form in which a substituent of said oxime can be C
1
-C
3
-alkyl substituted or not substituted by halogens; C
3
-C
7
-cycloalkyl; C
1
-C
5
-alkyl containing 1-3 ether bonds and/or an aryl substituent; substituted or not substituted phenyl; substituted or not substituted five or six ring-cycled heteroaryl containing more than one hetero atoms selected from a group consisting of nitrogen, sulfur and oxygen(wherein, phenyl or heteroaryl can be one- or multi-substituted by a substituent selected from a group consisting of hydrogen, methyl, ethyl and isopropyl); C
1
-C
3
-alkylcarbonyl; halogeno-C
1
-C
3
-alkylcarbonyl; C
3
-C
7
-cycloalkylcarbonyl; or C
1
-C
5
-alkylcarbonyl containing 1-3 ether bonds (—O—) and/or aryl substituent,
A and Q can be a nitrogen or oxygen atom independently, in which said nitrogen atom can be substituted by a substituent selected from a group consisting of hydrogen, methyl, ethyl and isopropyl.
The compound of the present invention can be a geometric isomer of a cis or a trans form and a mixture of these isomers, depending upon a substituent arranged around double bonds. Consequently, the geometric isomer or the mixture also can be within the scope and limit of the present invention.
The compound of the present invention can exist as a pharmaceutically acceptable salt form, wherein the pharmaceutically acceptable salt means a nontoxic salt containing organic salt and inorganic salt and accepted pharmaceutically. The inorganic salt consists of aluminum, ammonium, calcium, copper, iron, lithium, magnesium, manganese, potassium, sodium, zinc and the like and preferably, ammonium, calcium, magnesium, potassium, sodium. The organic salt consists of primary-, secondary- or tertiary-amines, naturally substituted amines, cyclic amines, modified salts prepared through basic ion exchange resin and the like. Preferably, the organic salt can be selected among arginine, betain, caffeine, colin, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, N-methylglucamine, glucamine, glucosamine, histidine, hydrapamine, N-(2-hydroxyethyl)piperidine, N-(2-hydroxyethyl)pyrrolidine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resin, procain, purine, teobromine, triethylamine, trimethylamine, tripropylamine, tromethamine and the like.
Besides, the compound of the present invention can be a salt form of nontoxic acids containing the organic acid and the inorganic acid and accepted pharmaceutically, in case that it be basic. Preferably, the acid can be adopted among acetic acid, adipic acid, aspartic acid, 1,5-naphthalenedisulfonic acid, benzenesufonic acid, benzo acid, camposulfonic acid, citric acid, 1,2-ethanedisulfonic acid, ethanesulfonic acid, ethylendiaminetetraacetic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, hydriodic acid, hydrobromic acid, hydrochloric acid, icethionic acid, lactic acid, maleic acid, malic acid, manderic acid, methanesulfonic acid, music acid, 2-naphthalene disulfonic acid, nitric acid, oxalic acid, parnoic acid, pantothenic acid, phosphoric acid, pivalic acid, propionic acid, salicylic acid, stearic acid, suc

Affiliated with

Also associated with

Rating

3,4-dihydro-1H-naphthalene derivatives as a highly selective... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 3,4-dihydro-1H-naphthalene derivatives as a highly selective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,4-dihydro-1H-naphthalene derivatives as a highly selective... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3289350